Trial Profile
Phase 1, Randomized, Double-Blind, Third-Party Open Placebo-Controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of PF-06823859 In Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2018
Price :
$35
*
At a glance
- Drugs Dazukibart (Primary) ; Dazukibart (Primary)
- Indications Lupus vulgaris
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Mar 2018 Data from this trial was used to develop population pharmacokinetic model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 24 Mar 2017 Status changed from recruiting to active, no longer recruiting.